Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave St, Miami, FL 3300, USA.
Medical Oncology (Impact Factor: 2.63). 10/2011; 29(3):1707-10. DOI: 10.1007/s12032-011-0093-8
Source: PubMed


Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) on day 1, 5-FU 750 mg/m(2) (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

8 Reads
  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Definitive chemoradiotherapy is the standard of care for T4 and/or M1 lymph node cancers. Although the treatment strategy would depend mainly on the diagnosis of T4 disease, the diagnosis of T disease is not standardized and cases of borderline resectable T4 disease are often encountered. We have administered the triplet regimen as intensive chemotherapy for cases of borderline resectable T4 disease. Methods We reviewed the records of patients with esophageal cancer who were treated between August 2009 and August 2010 at the Tochigi Cancer Center. Our treatment strategy for clinical stage II/III disease with unequivocal T4 disease in an adjacent organ was definitive chemoradiotherapy. Cases of clinical stage II/III disease with borderline resectable T4 disease were treated with preoperative chemotherapy via the triplet regimen of docetaxel and cisplatin plus 5-fluorouracil (DCF) followed by esophagectomy. Results Nine patients were treated with preoperative chemotherapy. Six patients with defined borderline T4 disease were treated with DCF. DCF toxicities were tolerable and all patients underwent subsequent surgery. The R0 resection rate was 66 % (4/6), although pathological T4 disease was found in 50 % of patients (3/6). There were no major complications or mortality, although the median blood loss and operation time were relatively higher with this regimen. Although 5 patients died of recurrence or coexisting disease, oral intake was maintained at the terminal stage. Conclusion Preoperative DCF followed by surgery seems to be a good option for select patients with T4 disease. Further investigations are warranted and a well-designed prospective trial is needed to draw a conclusion.
    Esophagus 12/2013; 10(4). DOI:10.1007/s10388-013-0384-6 · 0.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively compared preoperative docetaxel, cisplatin, and fluorouracil (DCF) with cisplatin and fluorouracil (CF) in patients with esophageal cancer. The study included patients with advanced thoracic esophageal carcinoma (excluding T4 tumors) receiving preoperative chemotherapy. In the DCF group, five patients received two courses of treatment every 4 weeks, and 33 patients received three courses every 3 weeks. In the CF group, 38 patients received two courses of treatment every 4 weeks. Patients underwent curative surgery 4-5 weeks after completing chemotherapy. Patient demographic characteristics did not differ between the two study groups. The incidence of a grade 3 or 4 hematologic toxicity was significantly higher in the DCF group (33 patients) than in the CF group (five patients; P < 0.001). Curative resection was accomplished in 79% of patients in the DCF group and 66% in the CF group (P = 0.305). There were no in-hospital deaths. The incidence of perioperative complications did not differ between the groups. A grade 2 or 3 histological response was attained in a significantly higher proportion of patients in the DCF group (63%) than in the CF group (5%; P < 0.001). Progression-free survival and overall survival were significantly higher in the DCF group (P = 0.013, hazard ratio 0.473; P = 0.001, hazard ratio 0.344). In conclusion, a grade 3 or 4 hematologic toxicity was common in the DCF group but was managed by supportive therapy. Histological response rate, progression-free survival, and overall survival were significantly higher in the DCF group compared with the CF group.
    Diseases of the Esophagus 02/2014; 28(2). DOI:10.1111/dote.12187 · 1.78 Impact Factor
Show more